Karl Hazel

Dr. Karl Hazel

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
PDF file
KHKarl Hazel
Karl Hazel
AOAnthony O’connor
Anthony O’connor
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation, a relapsing and remitting clinical course, requirement for lifelong medication and often, significant morbidity. While multiple effective therapeutic options exist for the treatment of IBD, a proportion of patients will either fail to respond or lose response to therapy. Advances in therapeutics, such as the gut-specific anti-integrins, now offer patients an alternative option to systemic immunosuppression. Anti-interleukin 12 (anti-IL-12)/IL-23 agents offer new and effective treatment options for CD, while the oral small molecules now offer an oral alternative for the treatment of moderate-to-severe disease, previously requiring subcutaneous injection or intravenous infusion. Alternatives to pharmacological treatment such as stem-cell transplant and faecal microbiota transplant are also showing some promise in the treatment of both CD and UC.

13 January 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
KHKarl Hazel
Karl Hazel
MSMairead Skally
Mairead Skally
EGEmily Glynn
Emily Glynn
MFMargaret Foley
Margaret Foley
KBKaren Burns
Karen Burns
FFFidelma Fitzpatrick
Fidelma Fitzpatrick

7 July 2026 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
JGJavier P Gisbert
Javier P Gisbert
MCMaría Chaparro
María Chaparro
BVBram Verstockt
Bram Verstockt
PKPeter Kienle
Peter Kienle
SMSilvia Minozzi
Silvia Minozzi
TKTorsten Kucharzik
Torsten Kucharzik

21 September 2024 in Digestive and Liver Disease
Verified
Journal Article
Closed access
CMCathy McShane
Cathy McShane
RVRachel Varley
Rachel Varley
AFAnne Fennessy
Anne Fennessy
CBClodagh Byron
Clodagh Byron
JCJohn Richard Campion
John Richard Campion
DKDavid Kevans
David Kevans

7 June 2026 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
MAMichel Adamina
Michel Adamina
PKPeter Kienle
Peter Kienle
MCMaría Chaparro
María Chaparro
BVBram Verstockt
Bram Verstockt
SMSilvia Minozzi
Silvia Minozzi
PMPär Myrelid
Pär Myrelid
This is the second of two articles presenting the European Crohn’s and Colitis Organisation [ECCO] evidence‑based consensus guidelines on the management of adult patients with ulcerative colitis [UC]. The first article covers the medical management of UC, including acute severe colitis. The present article addresses the surgical management of medically refractory UC, including the general surgical approach and perioperative optimisation, surgical strategies and techniques, and recommended levels of centre expertise and surgical specialisation. Together, these two articles aim to inform shared decision‑making and to guide clinicians and healthcare professionals involved in the care of patients with UC, drawing on the best available evidence.

26 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KHKarl Hazel
Karl Hazel
RCRachel Margaret Cooney
Rachel Margaret Cooney
Crohn’s disease is a chronic inflammatory bowel disease and, despite an increase in the available drug treatments, many patients will still require surgery at some point in their disease course. Stricturing and penetrating phenotypes of Crohn’s disease are less likely to respond to our current medical treatment and, therefore, surgical intervention may be required. This is most commonly elective, planned surgery, thereby affording the opportunity to optimize medications, nutritional and inflammatory status, and steroid use. Poor nutritional status and previous surgery increase the risk of postoperative complications. Preoperative optimization has three main goals: reduction of postoperative complications; reduction of reoperation rates; and reduction of postoperative recurrence rates. A literature search was completed using PubMed, Embase, and Ovid using the search term “preoperative optimization in Crohn’s disease”, and it included both adult and pediatric studies, excluding those for perianal Crohn’s disease. In this narrative review, we examine the role of nutritional intervention, medical optimization pre and postoperatively, and the role of personalized prehabilitation in the reduction of postoperative complications. We demonstrate that these may all yield better postoperative outcomes for patients with Crohn’s disease undergoing elective surgery, although the evidence is somewhat limited and there is a requirement for more prospective randomized controlled trials to implement their role into standard practice or guidelines.